Abstract: An initial position aligning unit performs initial positional alignment of a video and simulation data, and a position aligning unit performs positional alignment of the video and the simulation data. A first movement detecting unit detects movements of reference points which are set within a first image of the video, and a second movement detecting unit detects movement of a camera. A degree of reliability calculating unit compares the first and second movements to calculate a degree of reliability with respect to the movements of each of the reference points.

Abstract: When a virtual-endoscopic-image is generated from a three-dimensional-image representing a tubular-organ, a predetermined range is set in the vicinity of a viewpoint set in advance in the three-dimensional-image, and each of a lumen-region and a wall-region of the tubular-organ in the set range is identified. A voxel-value or a voxel-value-interval constituting a boundary between a range of voxel values in the identified lumen-region and a range of voxel values in the identified wall-region is obtained based on information about voxel-values in the identified lumen-region and information about voxel-values in the identified wall-region, and an opacity-curve representing a relationship between voxel values and opacity is set in such a manner that the opacity changes from a value representing a transparent-state to a value representing an opaque-state at the voxel-value or in the voxel-value-interval.

Abstract: An electric vacuum cleaner that secures efficiency and quietness without increasing the size of a main body part. The electric vacuum cleaner includes an electric blower, and a main body part including a first centrifugally separating part that centrifugally separates dust from air containing dust sucked by the electric blower. The first centrifugally separating part includes a dust collecting cup including a dust collecting cup main body that is formed into a bottomed cylindrical shape and turns air containing dust inside, and an exhaust tube part that is formed along the central axis of the dust collecting cup main body and discharges exhaust air of the electric blower from the bottom portion.

Abstract: An electric vacuum cleaner that can be improved in quietness without increasing in size while securing air intake balance. The electric vacuum cleaner includes an electric blower. The electric vacuum cleaner includes a separating part that separates dust sucked by the electric blower. The separating part includes a first centrifugally separating part that centrifugally separates dust sucked by the electric blower. The separating part includes a plurality of second centrifugally separating parts that centrifugally separates dust smaller than dust to be separated by the first centrifugally separating part. The second centrifugally separating parts communicate with the downstream side of the first centrifugally separating part, and are disposed at positions opposite to each other with respect to the electric blower.

Abstract: A 9-azabicyclo[3.3.1]nonan-3-one derivative is reacted with a hydrogen in the presence of a catalyst composed of a ruthenium complex to obtain, at a low cost, an endo-9-azabicyclo[3.3.1]nonan-3-ol derivative useful as a production intermediate for agrochemical agents or medicines.

Abstract: A three-dimensional medical image obtainment unit that obtains a three-dimensional medical image of a chest, a bronchial structure extraction unit that extracts a bronchial structure from the three-dimensional medical image, a divided lung region obtainment unit that divides, based on the divergence of the bronchial structure, the bronchial structure into plural bronchial structures, and obtains plural divided lung regions based on the plural divided bronchial structures, a distance image generation unit that generates, based on the plural divided lung regions, a distance image based on a distance between each voxel in an entire region excluding at least one of the plural divided lung regions and each of the plural divided lung regions, and a border non-existing region extraction unit that extracts, based on the distance image generated by the distance image generation unit, a border non-existing region, which does not include any borders of the divided lung regions, are provided.

Abstract: For assigning a binary label representing belonging to a target region or not to each pixel in an image: a predicted shape of the target region is set; a pixel group including N pixels is selected, where N is a natural number of 4 or more, which have a positional relationship representing the predicted shape; and an energy function is set, which includes an N-th order term in which a variable is a label of each pixel of the pixel group, so that a value of the N-th order term is at a minimum value when a combination of the labels assigned to the pixels of the pixel group is a pattern matching the predicted shape, and increases in stages along with an increase in a number of pixels to which a label different from the pattern is assigned. The labeling is performed by minimizing the energy function.

Abstract: When a virtual-endoscopic-image is generated from a three-dimensional-image representing a tubular-organ, a predetermined range is set in the vicinity of a viewpoint set in advance in the three-dimensional-image, and each of a lumen-region and a wall-region of the tubular-organ in the set range is identified. A voxel-value or a voxel-value-interval constituting a boundary between a range of voxel values in the identified lumen-region and a range of voxel values in the identified wall-region is obtained based on information about voxel-values in the identified lumen-region and information about voxel-values in the identified wall-region, and an opacity-curve representing a relationship between voxel values and opacity is set in such a manner that the opacity changes from a value representing a transparent-state to a value representing an opaque-state at the voxel-value or in the voxel-value-interval.

Abstract: A process is provided for efficiently producing an optically active 3-quinuclidinol derivative of high optical purity using a readily available ruthenium compound as an asymmetric reduction catalyst. This process is a process for producing an optically active 3-quinuclidinol derivative represented by the following formula (III) comprising asymmetrically hydrogenating a 3-quinuclidinone derivative represented by the following formula (I) in the presence of a ruthenium compound (II) represented by formula (II): Ru(X)(Y)(Px)n[R1R2C*(NR3R4)-A-R5R6C*(NR7R8)] (in the formulas, R represents a hydrogen atom or C7 to C18 aralkyl group and the like, X and Y represent hydrogen atoms or halogen atoms and the like, Px represents a phosphine ligand, n represents 1 or 2, R1 to R8 represent hydrogen atoms or C1 to C20 alkyl groups and the like, * represents an optically active carbon atom and A represents an ethylene group and the like).

Abstract: A three-dimensional medical image obtainment unit that obtains a three-dimensional medical image of a chest, a bronchial structure extraction unit that extracts a bronchial structure from the three-dimensional medical image, a divided lung region obtainment unit that divides, based on the divergence of the bronchial structure, the bronchial structure into plural bronchial structures, and obtains plural divided lung regions based on the plural divided bronchial structures, a distance image generation unit that generates, based on the plural divided lung regions, a distance image based on a distance between each voxel in an entire region excluding at least one of the plural divided lung regions and each of the plural divided lung regions, and a border non-existing region extraction unit that extracts, based on the distance image generated by the distance image generation unit, a border non-existing region, which does not include any borders of the divided lung regions, are provided.

Abstract: A continuous-region-extraction unit extracts a continuous-region having a voxel value corresponding to an air-region in bronchi from a three-dimensional-medical-image. A tree-structure-construction unit constructs a tree-structure corresponding to the continuous-region. A linear-structure-extraction unit extracts plural linear-structures representing fragments of small-bronchi by analyzing a local density structure in a neighborhood of each point in the three-dimensional-medical-image. A tree-structure-reconstruction unit reconstructs a graph-structure representing the whole bronchi by connecting a node constituting the graph-structure of large-bronchi and a node representing the linear-structures of small-bronchi. At this time, different cost functions are used for a segment connecting the node of the large-bronchi and the node representing the linear-structures of the small-bronchi and a segment connecting the nodes representing the linear-structures to each other.

Abstract: A process is provided for efficiently producing an optically active 3-quinuclidinol derivative of high optical purity using a readily available ruthenium compound as an asymmetric reduction catalyst. This process is a process for producing an optically active 3-quinuclidinol derivative represented by the following formula (III) comprising asymmetrically hydrogenating a 3-quinuclidinone derivative represented by the following formula (I) in the presence of a ruthenium compound (II) represented by formula (II): Ru(X)(Y)(Px)n[R1R2C*(NR3R4)-A-R5R6C*(NR7R8)] (in the formulas, R represents a hydrogen atom or C7 to C18 aralkyl group and the like, X and Y represent hydrogen atoms or halogen atoms and the like, Px represents a phosphine ligand, n represents 1 or 2, R1 to R8 represent hydrogen atoms or C1 to C20 alkyl groups and the like, * represents an optically active carbon atom and A represents an ethylene group and the like).

Abstract: It is to provide a novel optically active dibenzazepine derivative having a high utility value as an asymmetric phase-transfer catalyst. It is an optically active 6,7-dihydro-5H-dibenzo[c,e]azepine derivative represented by the following formula (1?), (wherein R represents a divalent organic group for cross-linking the 1st position and the 11th position; R1 and R2 are the same or different, and represent a hydrogen atom, halogen atom, or organic group, or R1 and R2 together represent a divalent organic group; R3? and R4? are the same or different and represent a monovalent organic group, or R3? and R4? together form an organic group that forms a cyclic structure comprising an onium nitrogen atom; Ar represents a monovalent organic group; * represents optical activity, i.e., that one axially asymmetric isomer is present in excess of the other axially asymmetric isomer with respect to a bond axis that constitutes the biphenyl structure of the compound; and X? represents a counter anion).

Abstract: A process is provided for efficiently producing an optically active 3-quinuclidinol derivative of high optical purity using a readily available ruthenium compound as an asymmetric reduction catalyst. This process is a process for producing an optically active 3-quinuclidinol derivative represented by the following formula (III) comprising asymmetrically hydrogenating a 3-quinuclidinone derivative represented by the following formula (I) in the presence of a ruthenium compound (II) represented by formula (II): Ru(X)(Y)(Px)n[R1R2C*(NR3R4)-A-R5R6C*(NR7R8)] (in the formulas, R represents a hydrogen atom or C7 to C18 aralkyl group and the like, X and Y represent hydrogen atoms or halogen atoms and the like, Px represents a phosphine ligand, n represents 1 or 2, R1 to R8 represent hydrogen atoms or C1 to C20 alkyl groups and the like, * represents an optically active carbon atom and A represents an ethylene group and the like).

Abstract: Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG. 1; a pharmaceutically acceptable salt thereof; a hydrate of the derivative or the salt; and a solvate of the derivative or the salt. (In the formula, R1 and R2 may be the same or different and each represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower alkoxy group, a haloalkyl group, a haloalkoxy group, an alkylsulfanyl group, an alkylsulfinyl group, an alkylsulfonyl group, a lower alkyl-substituted carbamoyl group, a saturated nitrogen-containing heterocyclic N-carbonyl group, a halogen atom, a cyano group or a hydrogen atom; R3 represents a lower alkyl group, a haloalkyl group, a halogen atom, a hydroxy group or a hydrogen atom; and X represents a sulfur atom, an —S(?O)— group or an —S(?O)2— group.

Abstract: Disclosed herein are optically active biphenol derivatives represented by the following formulas (1) and (2), a method for optically resolving a biphenol derivative represented by formula (2?), a production method of an optically active biphenol derivative (1) comprising a step for reacting a Brønsted acid with a biphenol derivative (2), and a production method of an optically active biphenol derivative (3) comprising a step for reacting a Lewis acid with an optically active biphenol derivative (1) or an optically active biphenol derivative (2).

Abstract: A touch panel glass substrate which can be manufactured simultaneously with other touch panel glass substrates, is free of microcracks in edges, and has predetermined strength, and a method for manufacturing the same are provided. An original glass plate as large as to cut out a plurality of glass substrates is prepared. Detection electrode traces and lead wiring traces on each glass substrate are simultaneously formed on the original glass plate. The original glass plate is then chemically etched to separate the touch panel glass substrates. The separation by chemical etching produces no microcracks in edges.

Abstract: Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG. 1; a pharmaceutically acceptable salt thereof; a hydrate of the derivative or the salt; and a solvate of the derivative or the salt. (In the formula, R1 and R2 may be the same or different and each represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower alkoxy group, a haloalkyl group, a haloalkoxy group, an alkylsulfanyl group, an alkylsulfinyl group, an alkylsulfonyl group, a lower alkyl-substituted carbamoyl group, a saturated nitrogen-containing heterocyclic N-carbonyl group, a halogen atom, a cyano group or a hydrogen atom; R3 represents a lower alkyl group, a haloalkyl group, a halogen atom, a hydroxy group or a hydrogen atom; and X represents a sulfur atom, an —S(?O)— group or an —S(?O)2— group.

Abstract: A novel ruthenium compound that is useful as an asymmetric reduction catalyst for carbonyl compounds. The ruthenium compound of the present invention is represented by a formula (I): (Ru(X)2(Pxx)[R1R2C(NH2)—R3R4C(NH2)] (I)), and when this compound is used as an asymmetric reduction catalyst, an optically active aminoalcohol compound can be produced from an ?-aminoketone, and particularly a compound represented by formula (IV), with high stereoselectivity and high yield.

Abstract: The present invention provides a method for analyzing agonist-activity to a cytokinin receptor, which comprises (1) bringing an examinee substance into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced and (2) measuring the existence or the quantity of intracellular signal transduction from the cytokinin receptor expressed in the transformed cell, and, a method for analyzing antagonist-activity to a cytokinin receptor, which comprises (1) bringing an examinee substance and a substance having agonist-activity to the cytokinin receptor into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced.